Why in News?
Lung cancer is heavily in the news following major medical breakthroughs in June 2026, most notably the discovery of a 14-protein "molecular signature" blood test that can predict lung cancer five years before diagnosis, alongside unprecedented clinical success from a triple-action tumour-eradicating therapeutic drug called amivantamab.
Medical Classification & Types
The disease originates when cells in the respiratory tracts grow uncontrollably, presenting in two main pathological classifications:
- Non-Small Cell Lung Cancer (NSCLC): The most prevalent form, accounting for approximately 85% of all documented cases. It includes adenocarcinomas and squamous cell carcinomas.
- Small Cell Lung Cancer (SCLC): Highly aggressive, fast-spreading subtype accounting for 13%–15% of cases, heavily associated with a history of intensive smoking.
Principal Risk Factors
- Tobacco Smoking: Remains the absolute leading driver, causing roughly 85% of all diagnoses globally.
- The Non-Smoker Surge: An increasing percentage of modern diagnoses occurs in individuals who have never smoked, predominantly impacting women.
- Environmental Toxins: Extended exposure to cancer-causing radon gas, secondhand smoke, asbestos, arsenic, and heavy diesel exhaust.
- Air Pollution: High fine particulate matter (PM 2.5) density in urban centers is directly linked to cellular mutations in lung tissues.
Symptoms and Clinical Warning Signs
Early stages are often asymptomatic, but developing malignancies display key physiological markers:
- A persistent, worsening cough that does not clear up after several weeks.
- Hemoptysis (coughing up blood or rust-coloured sputum).
- Shortness of breath (dyspnea), unexplained wheezing, and chronic chest pain.
- Unintended, rapid weight loss and severe fatigue.
Survival Metrics & Detection Challenges
- Global Fatality Leader: Statistically ranks as the No. 1 cause of cancer-related mortality globally, causing roughly 1.8 million deaths annually.
- Late-Stage Discovery Gap: Most cases are caught at Stage 3 or Stage 4 after local metastasis, because the lungs lack pain receptors to trigger early warning signs.
- Survival Disparity: Caught early, the 5-year survival rate stands at a strong 65%. However, if the cancer metastasizes to distant organs, the 5-year survival rate drops drastically to around 10%.
Modern Management & Treatment Pillars
Oncologists approach the disease using layered multi-modal treatment strategies:
- Surgical Resection: Physical removal of infected lung lobes (lobectomy) for localized early-stage tumours.
- Targeted Biomarker Therapy: Tailored drugs designed to explicitly block oncogenic mutations (such as EGFR inhibitors or ALK positive gene-targeted medications).
- Immunotherapy (Checkpoint Inhibitors): Monoclonal antibodies (like anti-PD-1 or PD-L1 agents) that unmask cancer cells, letting the patient’s own immune T-cells identify and destroy the tumour.
Download Pdf
